2022
Cerebrospinal Fluid Lymphocytic Pleocytosis is Associated With Enhanced Blood-Brain Barrier Breakdown at the Time of Multiple Sclerosis Diagnosis (P15-4.007)
Sivakolundu D, Kopyto M, Hill K, Elhusseiny H, Fulbright R, Hafler D, Longbrake E. Cerebrospinal Fluid Lymphocytic Pleocytosis is Associated With Enhanced Blood-Brain Barrier Breakdown at the Time of Multiple Sclerosis Diagnosis (P15-4.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2811.Peer-Reviewed Original Research
2006
Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
O’Connor K, Roy SM, Becker CH, Hafler DA, Kantor AB. Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers. Disease Markers 2006, 22: 213-225. PMID: 17124343, PMCID: PMC3851054, DOI: 10.1155/2006/670439.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMultiple sclerosisMagnetic resonance imagingPutative biomarkersComprehensive phenotypingMonitoring of progressionComponent expression levelsClinical evaluationCSF proteinAccurate biomarkersCerebrospinal fluid chemistryControl groupTherapeutic interventionsPatient careAccurate diagnosisResonance imagingDisease pathologyFurther evaluationBiomarkersPreliminary dataExpression levelsSclerosisDiagnosisCSFSingle testNovel assessment